TSHA
NASD Taysha Gene Therapies, Inc.$3.58 ↑ +0.00 (+0.00%) Trading Up from the previous close of $3.58, $0.55 below the day’s high of $4.13
- YTD change
- -34.91%
- vs 20-day SMA
- -25.00%
- vs 200-day SMA
- -33.93%
Price ranges
Price & Performance
-0.84 (-19.00%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 89.3% away from all-time highs of $33.35
- TSHA is down 35% since the beginning of the year
- TSHA is down 29% over the past 12 months
- TSHA is down 29% over the past 1 month
- 18% of all TSHA investors are betting against TSHA
TSHA reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -29.1%.
- Previous minute
- +$0.02
- Last hour
- -$0.02
- Last 5 days
- -20.27%
- vs 8-day SMA
- -19.87%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
